Research on the biology of chronic lymphocytic leukaemia (CLL) — a malignancy of CD5+ B cells — has profoundly enhanced the identification of patients who are at high risk of disease progression and the treatment of patients with drugs that target the distinctive features of CLL. This Primer highlights these advances, as well as the epidemiology, genetics and immunobiology of CLL.
- Thomas J. Kipps
- Freda K. Stevenson
- Kanti Rai